Literature DB >> 11423591

Infliximab treatment for Crohn's disease.

C A Conroy1, R Cattell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11423591      PMCID： PMC1760990          DOI： 10.1136/pmj.77.909.436

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  31 in total

1.  Treatment of fistulas in Crohn's disease with infliximab.

Authors:  R Löfberg
Journal:  Gut       Date:  1999-11       Impact factor: 23.059

2.  Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low.

Authors:  R J Farrell; Y Ang; P Kileen; D S O'Briain; D Kelleher; P W Keeling; D G Weir
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

3.  Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.

Authors:  G D'haens; S Van Deventer; R Van Hogezand; D Chalmers; C Kothe; F Baert; T Braakman; T Schaible; K Geboes; P Rutgeerts
Journal:  Gastroenterology       Date:  1999-05       Impact factor: 22.682

4.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Authors:  P Rutgeerts; G D'Haens; S Targan; E Vasiliauskas; S B Hanauer; D H Present; L Mayer; R A Van Hogezand; T Braakman; K L DeWoody; T F Schaible; S J Van Deventer
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

5.  An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

Authors:  E A Vasiliauskas; L Y Kam; M T Abreu-Martin; P V Hassard; K A Papadakis; H Yang; J B Zeldis; S R Targan
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

6.  Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

Authors:  E D Ehrenpreis; S V Kane; L B Cohen; R D Cohen; S B Hanauer
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

Review 7.  The relationship between infliximab treatment and lymphoma in Crohn's disease.

Authors:  S J Bickston; G R Lichtenstein; K O Arseneau; R B Cohen; F Cominelli
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

8.  6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity.

Authors:  D H Present; S J Meltzer; M P Krumholz; A Wolke; B I Korelitz
Journal:  Ann Intern Med       Date:  1989-10-15       Impact factor: 25.391

9.  Successful management of Crohn's disease of the ileoanal pouch with infliximab.

Authors:  E Ricart; R Panaccione; E V Loftus; W J Tremaine; W J Sandborn
Journal:  Gastroenterology       Date:  1999-08       Impact factor: 22.682

10.  Anal complications in Crohn's disease.

Authors:  D R Williams; J A Coller; M L Corman; F W Nugent; M C Veidenheimer
Journal:  Dis Colon Rectum       Date:  1981 Jan-Feb       Impact factor: 4.585
View more
  3 in total

1.  Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice.

Authors:  Akira Sakata; Takashi Ochiai; Hiroshi Shimeno; Sadao Hikishima; Tsutomu Yokomatsu; Shiroshi Shibuya; Akihisa Toda; Reiko Eyanagi; Shinji Soeda
Journal:  Immunology       Date:  2007-04-23       Impact factor: 7.397

2.  Post-Transcriptional Regulation of Hepatic DDAH1 with TNF Blockade Leads to Improved eNOS Function and Reduced Portal Pressure In Cirrhotic Rats.

Authors:  V Balasubramanian; G Mehta; H Jones; V Sharma; N A Davies; R Jalan; R P Mookerjee
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.379

3.  Interleukin-13 and interleukin-33 mRNA are underexpressed in the duodenal mucosa of German Shepherd dogs with chronic enteropathy.

Authors:  Aarti Kathrani; Victor Lezcano; Edward J Hall; Albert E Jergens; Yeon-Jung Seo; Jonathan P Mochel; Todd Atherly; Karin Allenspach
Journal:  J Vet Intern Med       Date:  2019-06-06       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.